Compare MYGN & GRPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | GRPN |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 654.9M |
| IPO Year | 1995 | 2011 |
| Metric | MYGN | GRPN |
|---|---|---|
| Price | $7.17 | $17.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 4 |
| Target Price | $12.58 | ★ $31.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $825,300,000.00 | $496,093,000.00 |
| Revenue This Year | $0.10 | $4.17 |
| Revenue Next Year | $5.28 | $10.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.21 | N/A |
| 52 Week Low | $3.76 | $9.21 |
| 52 Week High | $16.63 | $43.08 |
| Indicator | MYGN | GRPN |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 47.26 |
| Support Level | $6.93 | $16.47 |
| Resistance Level | $7.38 | $17.08 |
| Average True Range (ATR) | 0.39 | 0.92 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 39.88 | 70.34 |
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.